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Abstract
Background: Diabetes is a chronic medical condition and adherence to medication in diabetes is important.
Improving medication adherence in adults with diabetes would help prevent the chronic complications associated
with diabetes. A case control trial was used to study the effects of an educational session on medication adherence
among adults with diabetes as measured by the Morisky Medication adherence scale (MMAS-8©).
Methods: The study took place at the Dubai Police Health Centre between February 2015 and November 2015.
Questionnaires were used to collect socio-demographic, clinical and disease related variables and the primary
measure of outcome was adherence levels as measured by the Morisky Medication Adherence Scale (MMAS-8©).
The intervention group involved a standardized thirty minute educational session focusing on the importance of
adherence to medication. The change in MMAS-8© was measured at 6 months.
Results: Four hundred and forty six patients were enrolled. Mean age 61 year +/− 11. 48.4 % were male. The mean
time since diagnosis of diabetes was 3.2 years (Range 1–15 years). At baseline two hundred and eighty eight (64.6 %)
patients were considered non-adherent (MMAS-8© adherence score < 6) while 118 (26.5 %) and 40 (9.0 %) had low
adherence (MMAS-8© adherence score < 6) and medium adherence (MMAS-8© adherence scores of 6 to 7) to their
medication respectively. The percentage of patients scoring low adherence MMAS-8 scores in the interventional group
dropped from 64.60 % at baseline to 44.80 % at 6-months (p = 0.01). There was no obvious change in the
adherence scores at baseline and at 6-months in the control group. Based on the study data, the Wilcoxon
signed-rank test showed that at 6 months, the educational 30-min session on diabetes and adherence to medication
did elicit a statistically significant change in adherence levels in adults with diabetes enrolled in the intervention arm
(Z = −6.187, p <0.001).
Conclusion: Adults with diabetes would benefit from educational sessions focusing on the importance of adherence
to medication. Public health strategies should focus on wider educational strategies targeting medication adherence in
diabetic patients in the UAE.
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IPAQ, International physical activity questionnaire; MMAS-8, Morisky medication adherence scale- 8; U.A.E., United Arab
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Background
Diabetes mellitus is a chronic metabolic disease affecting
approximately 341 million to 371 million people world-
wide [1, 2]. Furthermore, it is estimated that one third of
those affected (approximately 122.5 million) are not
aware that they have the condition [3].
The oil boom has led to a massive increase in the
GDP and disposable income of the people of the
United Arab Emirates (UAE). The UAE was ranked as
the 19th highest income countries of the world in
2012 (International Monetary Fund) and is catego-
rized as a high income country according to the
(World bank, 2012). This has led to a more affluent
lifestyle, and from health point an increase in total
calorie intake per person together with a decrease in
calorie expenditure. This has led to a nationwide
obesity pandemic with the rates of obesity climbing
to record highs and standing at about 68 % of the
population according to one estimate from 2007 .
The UAEis now listed as the country with the 11th
highest prevalence of diabetes globally (primarily type-2)
[4]. Furthermore, metabolic control of diabetes is report-
edly poor, leading to an increased risk of associated
complications [5]. Almost 70 % of Emirati nationals are
reported to be overweight or obese [6], and one third of
Emirati children are also now obese [7]; these figures are
two to three times those of international standards [8],
thus, it is unsurprising that the prevalence of type-2 dia-
betes has escalated.
Medication non-adherence is of increasing concern for
healthcare providers despite the known benefits of mod-
ern treatment regimens, with prevalence reported in one
study to be in excess of 50 % of diabetic patients. The
consequences of non-adherence include not only health-
related consequences (i.e. failure of treatment, rehospita-
lisation, death), but also financial consequences as the
cost of emergency medical interventions as a conse-
quence of non-adherence outweigh the combined cost
of an adhered-to medication regimen [9]. The WHO has
identified non-adherence as a multifactorial problem
caused by the interplay of factors from any of the follow-
ing 5 areas: 1) the patient, 2) the condition, 3) the type
of therapy prescribed, 4) socioeconomic factors, and 5)
health system related factors [10]. Several studies have
been carried out looking at medication adherence in dia-
betic patients around the world; however no studies have
been performed in the U.A.E [11–13].
Methods
Study design
A case control trial was used to study the effects of an
educational session on medication adherence among
adults with diabetes as measured by the Morisky Medi-
cation adherence scale (MMAS-8©). Patients were
randomized to standard care (control group) or standard
care plus an educational session (intervention group) on
the importance of adherence to medication. The
MMAS-8 © scores were collected via questionnaires at
baseline and at the end of the study. The change in
MMAS-8 © scores was analysed using statistical soft-
ware. The research topic was granted an ethical clear-
ance through the Human Research Ethics Committee at
Griffith University GU Ref No: PBH/11/14/HREC and
confirmed with the Dubai Police Research Ethics
standards.
Study setting
The study took place at the Dubai Police Health Services
Clinic between February 2015 and November 2015. This
centre provides primary care and speciality care for all
Dubai Police employees and members of their families
and had over 200,000 clinic visits in 2014 alone.
Procedures (Fig. 1)
Inclusion criteria
All patients were type 2 adults with diabetes on at least
one anti-diabetic medication following a diabetes diag-
nosis of 1 year or more. Male and female patients be-
tween the age of 18 and 80 years were eligible for the
study. The following exclusions applied: cognitive im-
pairment, pregnant or breast feeding women, non-
residents and patients who did not comprehend either
the English or Arabic language.
The investigators identified and screened potential
participants in the following manner: all patients present
in the waiting area of the diabetic clinic were asked if
they were willing to talk to the investigator. If the person
agreed, then an informed consent was read and ex-
plained by the investigators. Once verbal consent was
obtained, the inclusion and exclusion criteria were
checked.
Data was collected primarily via questionnaires. Pa-
tients were asked to fill in these questionnaires in order
to gather demographic information and information re-
garding motivations and associated behaviours. These
questionnaires were written using the Android Database
software package (MEMENTO). The questionnaires
were then handed out in electronic form using an An-
droid tablet. The tablets were purchased for the purpose
of this research and were solely used for this purpose.
These tablets were secured with an encrypted password
and were locked in drawer at the research office when
not in use. The tablets and questionnaires were super-
vised by one of the research investigators at the time of
interview to ensure the correct handling of the question-
naire and to troubleshoot any problems if they would
arise. The questionnaire forms were based on a number
of field styles including free text, date, single best answer
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and multi-check selections. The database software col-
lated the results into an excel sheet which was later
exported to a computer for further data analysis. All par-
ticipants completed the questionnaires in a private clinic
room.
A simple random number generator was used to ran-
domly allocate patients to either the control group or
the intervention group. The intervention group then
went on to attend a 30-min education session about
diabetes and its associated medication (this group is re-
ferred to as the ‘intervention group’), whilst the other
group was not invited to attend this session, and instead
received the same level of education regarding diabetes
as is offered as standard from UAE healthcare providers
(this group is referred to as the ‘control group’). Follow-
ing which, the intervention group received a weekly
phone call to check on their progress for the duration of
3 months, the control group were not eligible for these
Fig. 1 Recruitment and randomization process
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phone calls. The follow-up phone call served more of a
motivational strategy by asking the patients standardized
questions like: 1- Do you have any concerns about your
diabetes medication? – Interviewer to try and answer
the patients concerns and refers to clinician as appropri-
ate. 2- Did you face circumstances that have prevented
you from picking up your medication from your phar-
macy? Interviewer: To try and address these concerns
and refer to social worker as appropriate.
The patients were then re-invited to undertake the
questionnaires at 6 months from the time of their initial
visit in order to determine any long-term improvements
in medication adherence. Furthermore, whole blood
samples were collected by venepuncture from all pa-
tients at their initial and 6-month visits in order to de-
termine HbA1c concentrations.
Educational session on adherence to medication
Patients randomized to the intervention arm were sub-
jected to a 30 min educational session focusing on the
importance of medication adherence. The educational
session was undertaken by a diabetes nurse and con-
sisted of a 30 min session aided with a PowerPoint pres-
entation based on slides adopted from the International
Diabetes Federation (IDF) education modules published
online in 2011. The PowerPoint presentation was struc-
tured around medication adherence and compliance.
The importance of medication adherence as well as bar-
riers to self-management were covered and explained by
covering the following themes:
Check that the patient understands when and how
they should take their medicine.
Ask the patient when they will take the medicine.
Explain the benefits of the medicine—stress the fact
that patients may not have any symptoms of diabetes or
feel at all ill; therefore unlikely that the medicine will
make them “feel better”.
Be sure it is understood that the medicine is having a
beneficial effect inside the body.
Ensure that people know what to expect in terms of
side effects, and that these might only be short term;
thus people will be more likely to continue with the
medicine (another reason people stop is that they did
not like the side effects).
The aim of the interview was to educate the patients
on the importance of medication and the importance of
adherence in the long term on the outcomes of their
diabetes. Breifly, the investigators would have explained
the action of each diabetes medication, the time at which
the medication was to be taken and the benefits of tak-
ing these medications. These points would have re—in-
forced the patients’ knowledge on diabetes management
and medication compliance.
The didactive nature of the slide show presentation
was coupled with a more collaborative approach where
the diabetes educator would encourage the patient to
ask questions about medication adherence and answer
those questions.
Data variables
The data collated via the questionnaires included the fol-
lowing variables: age, gender, ethnicity, marital status,
highest level of education attained, working conditions,
transport availability, smoking status, diabetes duration,
cultural factors (dress wear, behaviors in Ramadan, per-
ception towards obesity), number of anti-diabetic medi-
cation, insulin therapy, the Depression, Anxiety and
Stress scale (DASS-21) and International Physical Activ-
ity Questionnaire (IPAQ) score. The Morisky Medication
Adherence Scale −8 (MMAS-8) score was used to meas-
ure the outcome of adherence to medication. MMAS-8.
The Glycated Haemoglobin test (HbA1c (%)) was used
to check the validity of the MMAS-8 score in this cohort
as a measure of adherence to medication among the
study participants. IBM SPSS-20 was used for statistical
analyses.
Morisky medication adherence scale The Morisky
Medication Adherence Scale (MMAS) was designed to
determine adherence behaviours [14]. For this study the
8-item model of this scale was used; patients were asked
8 questions (Table 1) designed to determine which fac-
tors affect how well they adhered to their medication
Table 1 The 8 questions asked to determine medication
adherence based on the morisky medication adherence scale
Questions
1. Do you sometimes forget to take your medicine?
2. People sometimes miss taking their medicines for reasons other than
forgetting. Thinking over the past 2 weeks, were there any days when
you did not take your medicine?
3. Have you ever cut back or stopped taking your medicine without
telling your doctor because you felt worse when you took it?
4. When you travel or leave home, do you sometimes forget to bring
along your medicine?
5. Did you take all your medicines yesterday?
6. When you feel like your symptoms are under control, do you
sometimes stop taking your medicines?
7. Do you ever feel hassled about sticking to your treatment plan?
8. How often do you have difficulty remembering to take all your
medicine?
1. Never
2. Once in a while
3. Sometimes
4. Usually
5. All the time
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regimen. Patients are required to answer the questions
with either a ‘yes’ or a ‘no’, with the final question taking
the form of a typical five-point Likert item. Positive an-
swers (i.e. yes) are scored a 1 and negative answers (i.e.
no) are scored a 0. From these responses a final score
was calculated with three possible outcomes; a score of
>2 corresponded to low medication adherence, a score
of 1 or 2 corresponded to medium medical adherence,
and a score of 0 corresponded to high medical adher-
ence. The MMAS is a popular, easy and economical
method of data collection, facilitating the collection of a
large amount of data in a short period of time [15].
Results
A total of 513 patients were identified as meeting the
study inclusion criteria, and 442 patients agreed to
take part of the study. There were no patients lost to
follow-up (Fig. 1). There were 223 patients in the
control group and 223 patients in the control group.
The baseline characteristics were well distributed be-
tween the two groups with no significant differences
among the two groups. 48.4 % (n = 216) of patients
were male. The mean time since diagnosis of diabetes
was 3.2 years (Range 1–15 years). Emaratis repre-
sented 56.1 % of the study population patients,
followed by Arab Non Emarati patients (38.1 %) and
Asian patients (5.8 %) (Tables 2 and 3).
Two hundred and eighty eight (64.6 %) patients were
considered non-adherent (MMAS-8© adherence score
<6) while 118 (26.5 %) and 40 (9.0 %) had medium ad-
herence (MMAS-8© adherence score 6 to 7) and high
adherence (MMAS-8© adherence scores of <8) to their
medication respectively (Fig. 2).
The strongest predictor for adherence as predicted
by the multi-logistic regression model was the pa-
tient’s level of education. A technical diploma certificate
as compared to a primary school level of education was
the strongest predictor of adherence (OR = 66.1 CI: 6.93 to
630.43); p < 0.001). The patient’s age was also a predictor
of adherence with older patients reporting higher levels of
adherence (OR = 1.113 (CI: 1.045 to 1.185; p = 0.001 for
every year increase in age). The duration of diabetes was
also a predictor of adherence (OR = 1.830 (CI: 1.270 to
2.636; p = 0.001 for every year increase in the duration of
diabetes). Other predictors to medication adherence in-
clude Insulin use, ethnicity and certain cultural behaviours
(Fig. 3).
Reliability, internal consistency and validity of MMAS-8
The Cronbach’s alpha test was calculated for the 8-item
MMAS-8 and this was reliable at 0.736 Omission of any
of the 8-items of the MMAS-8 questionnaire resulted in
a lower Cronbach’s alpha. The validity of MMAS-8 ad-
herence score was assessed by testing the ability of the
score to distinguish between groups of individuals that
differ from each other according to the HbA1c. There
was a significant difference in the Mean HbA1c levels
among the three adherence groups. Mean HbA1c was
Table 2 Baseline characteristics
Randomization
Group
Control Intervention
Age (mean +/− std) 61a 62a
+/− 11 +/− 11
Gender Female 52.0 %a 51.1%a
116 114
Male 48.0 %a 48.9%a
107 109
Ethnicity Arab Emarati 53.8%a 58.3%a
120 130
Arab Non-
Emarati
40.8%a 35.4 %a
91 79
Asian 5.4 %a 6.3 %a
12 14
HbA1c baseline (mean +/− std) 8.50a 8.49a
.09 .10
SBP at baseline (mean +/− std) 134a 133a
26 26
DBP at baseline (mean +/− std) 72a 73a
20 21
HDL at baseline (mean +/− std) 54a 54a
11 11
LDL at baseline (mean +/− std) 130a 129a
36 37
TGL at baseline (mean +/− std) 207a 216b
42 41
Anti-Diabetic therapy Monotherapy 27.8%a 30.9%a
62 69
Combination 72.2%a 69.1%a
161 154
Insulin use Yes 49.8%a 50.7 %a
111 113
No 50.2%a 49.3%a
112 110
Prescence of Chronic
conditions
Yes 52.9%a 55.2%a
118 123
No 47.1%a 44.8%a
105 100
Note: Values in the same row and subtable not sharing the same subscript are
significantly different at p < .05 in the two-sided test of equality for column
proportions. Cells with no subscript are not included in the test. Tests assume
equal variances.1
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9.24, 7.33 and 6.60 % in the low, medium and high ad-
herence groups respectively (p < 0.05).
Adherence as measured by the MMAS-8 ordinal scores
Descriptive statistics of the data analysed showed a sig-
nificant increase in the adherence levels in the interven-
tional arm. The percentage of patients scoring low
adherence MMAS-8 scores in the interventional group
dropped from 64.60 % at baseline to 44.80 % at 6-
months (p = 0.01). Meanwhile there was no obvious
change in the adherence scores at baseline and at 6-
months in the control group (Fig. 4).
Interventional arm
Based on the study data, the Wilcoxon signed-rank test
showed that at 6 months, the educational 30-min session
on diabetes and adherence to medication did elicit a sta-
tistically significant change in adherence levels in patients
enrolled in the intervention arm (Z = −6.187, p <0.001).
The median MMAS-8 Score rating was 1.0 (Low adher-
ence) pre-intervention and 2.0 (medium adherence) post-
intervention.
Control arm
On the other hand, the Wilcoxon signed-rank test
showed that at 6 months, there was no statistically sig-
nificant change in adherence levels in patients in the
control group (Z = −1.528, p =0.127). The median
MMAS-8 Score rating was 1.0 (Low adherence) at base-
line and at 6 months.
Changes in HbA1c
The mean HbA1c at 6 months was compared to the
baseline mean HbA1c in both the Intervention and Con-
trol groups using the paired samples T-test. The T-test
showed a significant decrease in mean HbA1c at 6-
months in the intervention group from baseline (8.5 vs
7.2 % p < 0.001). At the same time there was a non-
significant decrease in HbA1cn the control group (8.50
vs 8.45 % p = 0.079) Table 4.
Discussion
Limited data exist on the adherence of diabetics in the
United Arab Emirates to their medication prescribed by
their doctors as well as on the factors influencing their
adherence. This single centre case control study of 442
Table 3 Adherence levels against different demographic variables
Adherence level
Low Adherence
(MMAS-8 < 6)
Medium Adherence
(MMAS-8 = 6 to 7)
High Adherence
(MMAS-8 = 8)
Row % Column % n Row % Column % n Row % Column % n
Marital Status Single 70.4 % 6.6%a 19 18.5 % 4.2%a 5 11.1 % 7.5%a 3
Married 66.0 % 88.2%a 254 26.5 % 86.4%a,b 102 7.5 % 72.5%b 29
Divorced 51.9 % 4.9%a 14 37.0 % 8.5%a 10 11.1 % 7.5%a 3
Widowed 14.3 % 0.3 %a 1 14.3 % 0.8%a 1 71.4 % 12.5%b 5
Living arrangements Alone 79.0 % 17.0 %a 49 17.7 % 9.3%a 11 3.2 % 5.0 %a 2
Partner with children 63.9 % 75.7 %a 218 26.7 % 77.1%a 91 9.4 % 80.0 %a 32
Partner with no children 42.9 % 2.1%a 6 28.6 % 3.4%a,b 4 28.6 % 10.0 %b 4
Single adult with children 50.0 % 3.5%a 10 45.0 % 7.6 %a 9 5.0 % 2.5%a 1
Other family members 55.6 % 1.7%a 5 33.3 % 2.5%a 3 11.1 % 2.5%a 1
Level of Education Primary/Secondary school 76.8 % 36.8%a 106 21.0 % 24.6%a,b 29 2.2 % 7.5%b 3
High school school 79.7 % 34.0%a 98 17.9 % 18.6%b 22 2.4 % 7.5%b 3
Technical diploma 43.3 % 13.5%a 39 46.7 % 35.6%b 42 10.0 % 22.5%a,b 9
University degree 47.4 % 15.6%a 45 26.3 % 21.2%a 25 26.3 % 62.5%b 25
Working conditions Employed 63.6 % 85.4 %a 246 27.4 % 89.8%a 106 9.0 % 87.5%a 35
Unemployed 81.1 % 10.4%a 30 18.9 % 5.9%a 7 0.0 % 0.0 %
1 0
Retired 42.9 % 2.1%a 6 21.4 % 2.5%a 3 35.7 % 12.5%b 5
Sickness beneficiary 75.0 % 2.1%a 6 25.0 % 1.7%a 2 0.0 % 0.0 %
1 0
Transportation Avaliability No 70.4 % 6.6 %a 19 29.6 % 6.8%a 8 0.0 % 0.0 %
1 0
Yes 64.2 % 93.4%a 269 26.3 % 93.2%a 110 9.5 % 100.0 %
1 40
Note: Values in the same row and subtable not sharing the same subscript are significantly different at p < .05 in the two-sided test of equality for column
proportions. Cells with no subscript are not included in the test. Tests assume equal variances.2
1. This category is not used in comparisons because its column proportion is equal to zero or one
2. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni correction
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patients in the United Arab Emirates primarily looked at
the utility of an educational session at increasing the
levels of medication adherence among patients with dia-
betes. The results showed an increase in the MMAS-8
adherence scores with the percentage of non-adherents
dropping from 65 to 45 %.
Studies in other countries have demonstrated poor ad-
herence rates of medication among diabetics and pa-
tients suffering with other chronic conditions. Al
Mazroui demonstrated a significant reduction in the
levels of HbA1c among diabetics receiving an intensive
educational program over a 12 month period of time
Fig. 2 Rates of adherence according to MMAS-8 scores
Fig. 3 Predictors to medication adherence
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(baseline vs. 12 months; 95 % confidence interval) of
HbA1c8.5 % (8.3, 8.7) vs. 6.9 % (6.7, 7.1) [16]. Reed dem-
onstrated the important role of chronic diabetes clinics
in the UAE at improving diabetes outcomes as measured
by HbA1c levels and blood pressure. However, neither of
the former ‘UAE based’ studies had been designed to
study the levels of adherence to medication among
diabetics [17].
Despite this lack of data from the United Arab Emir-
ates and the Arab world as a whole, there have been nu-
merous studies from around the world looking at the
impact of medication adherence on outcome in patients
of chronic medical diseases including diabetes. An
American observational study concluded that high ad-
herence levels to medication among diabetics were asso-
ciated with an overall reduction in healthcare costs [18].
Another retrospective study of over 11,000 patients
showed that poorly non-adherent diabetics had higher
all-cause hospitalization and all-cause mortality com-
pared to adherent diabetics [9]. Adherence to medica-
tion in diabetes is therefore of upmost importance, and
identifying factors that lead to poorer medication com-
pliance should be identified to guide healthcare policy.
Non-adherence may arise as a consequence of the pa-
tient knowingly disregarding their treatment regimen
(active non-adherence), or as a consequence of careless-
ness or forgetfulness, whereby patients occasionally omit
their medication from their daily routine or take that
medication later than required (passive non-adherence).
The WHO has identified non-adherence as a multifac-
torial problem caused by the interplay of factors from
any of the following 5 areas: 1) the patient, 2) the condi-
tion, 3) the type of therapy prescribed, 4) socioeconomic
factors, and 5) health system related factors (WHO,
2001). This complex interaction of different factors lead-
ing to non-adherence has been studied by many groups
around the world. In Italy, Viana et al. published a meta-
analysis of RCTs in patients with type-1 diabetes which
focused on psychological, telecare and educational inter-
ventions to improve treatment compliance. This meta-
analsysis has shown that psychological approaches to
improve adherence to diabetes care treatment modestly
reduced HbA1c in patients with type 1 diabetes; telecare
and education interventions however did not change gly-
cemic control [19].
Koenisberg et al. have shown that reviewing patient
goals and treatment regimens at regular intervals (e.g.
monthly, biannually, or annually) has been shown to
help patients to persist in adhering to their treatment
plan [20]. Encouraging patients to monitor their own
progress is also important in order for long-term adher-
ence to be successful; it is important, however, for pa-
tients to develop their own record system to ensure they
maximise their chances of adhering to a long-term
Fig. 4 MMAS-8 adherence levels at baseline and 6-months
Table 4 Mean HbA1c levels at baseline and 6-months
Mean N Std. Deviation Std. Error Mean
Control Baseline HbA1c(%) 8.5018 223 1.39820 .09363
6-months HbA1c(%) 8.4515 223 1.35603 .09081
Intervention Baseline HbA1c(%) 8.4892 223 1.42859 .09567
6-months HbA1c(%) 7.1533 223 1.63739 .10965
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treatment plan. Flexibility in treatment options is also
important as patients are more likely to achieve their
goals using treatments they feel more comfortable with.
Education has been identified as a major barrier to ad-
herence to clinical interventions. Patient counselling to
improve patient knowledge of the disease and the bene-
fits of both medical intervention and lifestyle changes
has been introduced. Coaching is also now available to
encourage positive lifestyle choices, empower patients, de-
velop self-sufficiency and assist patients in identifying and
overcoming their own barriers to adherence .
In our cohort of patients the strongest independent
predictor of adherence was the patient’s education
level. A technical diploma certificate as compared to
a primary school level of education was the strongest
predictor of adherence (OR = 66.1 CI: 6.93 to 630.43);
p < 0.001). Educational websites have been set up in
order to raise health literacy and allow an anonymous
forum in which patients can clarify any issues which
may be preventing medication adherence. However
many patients lack access to such resources. Further-
more, tailoring specific exercise plans and personalis-
ing diet plans may also help patients achieve their
lifestyle-change goals. This study of type 2 diabetes
patients in the United Arab Emirates explored the
utility of an educational session on improving medica-
tion adherence. The adherence rates among adults
with diabetes in this group of patients followed
through a primary care setting were extremly low
(64.6 % of patients were considered non-adherent
with a MMAS-8© adherence score < 6).
The data analysed showed an obvious increase in
the adherence levels in the interventional arm. The
percentage of patients scoring low adherence MMAS-
8 scores in the interventional group dropped from
64.60 % at baseline to 44.80 % at 6-months (Pearson
Chi-square p = 0.01). Meanwhile there was no obvious
change in the adherence scores at baseline and at 6-
months in the control group.
Based on the study data, the Wilcoxon signed-rank
test showed that at 6 months, the educational 30-min
session on diabetes and adherence to medication did
elicit a statistically significant change in adherence levels
in diabetics enrolled in the intervention arm (Z = −6.187,
p <0.001). The median MMAS-8 Score rating was 1.0
(Low adherence) pre-intervention and 2.0 (medium ad-
herence) post-intervention.
The patients in this study were individually subjected
to the educational session which was both time-
consuming and man-power intensive. This could be fa-
cilitated in the future by asking patients to attend group
sessions that could also touch upon other aspects of dia-
betes besides medication compliance. The Desmond trial
showed that a structured group education programme
for patients with newly diagnosed type 2 diabetes re-
sulted in greater improvements in weight loss and smok-
ing cessation and positive improvements in beliefs about
illness but there were no differences in HA1c levels up
to 12 months after diagnosis [21]. Trento et al. has also
shown in an RCT over a 5-year period that group care
and education of patients with diabetes was associated
with better quality of life and knowledge of diabetes
compared to control individual care [22].
The intial interview consisted of only 30 min of
“one-on-one” time between the interviewer and the
patient. This time is shorter when compared to the
time utilitized in group intervention programmes. For
example, Weinger et al. has shown that a structured
behavioral intervention consisting of five 2-hour ses-
sions, delivered over 6 weeks, of highly structured
behavior-based activities and information was effective
in improving glycemia in adults with long-duration
diabetes. The limitations of this study include the
small size, which despite meeting the pre-determined
study size sample predicted before starting the study
would continue to be a source of population bias
error. The MMAS is a popular, easy and economical
method of data collection, facilitating the collection of
a large amount of data in a short period of time. Fur-
thermore, the questions are purposely phrased to
avoid the ‘yes-saying’ bias as it is known that patients
feel they should provide healthcare providers with a
positive response. However, there are limitations to
this method of data collection; the MMAS does not
account for personal or lifestyle factors (e.g. age,
physical ability, means of transport, known methods
of communication, etc.), and the outcome of these
questions can be biased by patients supplying false in-
formation. There was no direct measurement of ad-
herence to medication however the MMAS-8 score
has been well validated in measuring medication ad-
herence in diabetes and other chronic conditions.
Conclusion
Adherence to medication among diabetics in the
U.A.E. continues to be low. In this study there was a
significant improvement in the adherence to medica-
tion in diabetics taking part in an educational session
focusing on the importance of anti-diabetes medica-
tion and adherence to it. The results of such a pilot
program would be of upmost value in supporting the
implantation of bigger trials or even a national educa-
tional program in the UAE which up to today is still
lacking. Public health policy makers in the U.A.E.
should be equipped and ready with all the knowledge
to get services ramped up quickly as the ‘Diabetes
Tsunami’ hits its shores.
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